Sobi's pozdeutinurad lowers serum urate levels in Phase 3 gout trial

PUBT · 11/03 07:11
Sobi's pozdeutinurad lowers serum urate levels in Phase 3 gout trial
  • Sobi will present six gout research abstracts at ACR Convergence 2026, taking place November 6-11 in Orlando, Florida.
  • Phase 3 REDUCE-2 results, scheduled for presentation November 11, show pozdeutinurad lowered serum urate levels in patients with gout.
  • November 9-10 presentations will cover Phase 3 NASP safety analyses and treatment-stopping rules for uncontrolled gout, alongside patient-focused research.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.